Chémobiologie
Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 4, Avril 2015
Chémobiologie
Page(s) 423 - 431
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153104017
Publié en ligne 8 mai 2015
  1. Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012 ; 11 : 17–18. [CrossRef] [PubMed]
  2. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 2013 ; 18 : 1067–1073. [CrossRef] [PubMed]
  3. Prudent R, Vassal-Stermann E, Nguyen CH, et al. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res 2012 ; 72 : 4429–4439. [CrossRef] [PubMed]
  4. Moucadel V, Prudent R, Sautel CF, et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2011 ; 2 : 997–1010. [PubMed]
  5. Prudent R, Moucadel V, Nguyen CH, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010 ; 70 : 9865–9874. [CrossRef] [PubMed]
  6. Lopez-Ramos M, Prudent R, Moucadel V, et al. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. FASEB J 2010 ; 24 : 3171–3185. [CrossRef] [PubMed]
  7. Prudent R, Hasenknopf B, Cochet C Les polyoxométallates : des inhibiteurs inorganiques de la protéine kinase CK2. Med Sci (Paris) 2008 ; 24 : 1012–1014. [CrossRef] [EDP Sciences] [PubMed]
  8. Prudent R, Moucadel V, Laudet B, et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008 ; 15 : 683–692. [CrossRef] [PubMed]
  9. Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem Biol 2009 ; 16 : 112–120. [CrossRef] [PubMed]
  10. Hibert MF. French/European academic compound library initiative. Drug Discov Today 2009 ; 14 : 723–725. [CrossRef] [PubMed]
  11. Prudent R, Soleilhac E, Barette C, et al. Les criblages phénotypiques ou comment faire d’une pierre deux coups. Med Sci (Paris) 2013 ; 29 : 897–905. [CrossRef] [EDP Sciences] [PubMed]
  12. Hoang TMN, Favier B, Valette A, et al. Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases. Cell Cycle 2009 ; 8 : 765–772. [CrossRef] [PubMed]
  13. Camara D, Bisanz C, Barette C, et al. Inhibition of p-aminobenzoate and folate syntheses in plants and apicomplexan parasites by natural product rubreserine. J Biol Chem 2012 ; 287 : 22367–22376. [CrossRef] [PubMed]
  14. Boussouar A, Barette C, Nadon R, et al. Acacetin and chrysin, two polyphenolic compounds, alleviate telomeric position effect in human cells. Mol Ther Nucleic Acids 2013 ; 2 : e116. [CrossRef] [PubMed]
  15. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 ; 105 : 2640–2653. [CrossRef] [PubMed]
  16. Kawasumi M, Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J Invest Dermatol 2007 ; 127 : 1577–1584. [CrossRef] [PubMed]
  17. O’Connor CJ, Laraia L, Spring DR. Chemical genetics. Chem Soc Rev 2011 ; 40 : 4332–4345. [CrossRef] [PubMed]
  18. McPherson A, Nguyen C, Cudney R, et al. The role of small molecule additives and chemical modification in protein crystallization. Cryst Growth Des 2011 ; 11 : 1469–1474. [CrossRef]
  19. Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007 ; 43 : 928–934. [CrossRef] [PubMed]
  20. Giusiano S, Cochet C, Filhol O, et al. Protein kinase CK2alpha subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. Eur J Cancer 2011 ; 47 : 792–801. [CrossRef] [PubMed]
  21. Buchou T, Cochet C. La protéine kinase CK2, une enzyme qui cultive la différence. Med Sci (Paris) 2003 ; 19 : 709–716. [CrossRef] [EDP Sciences] [PubMed]
  22. Filhol O, Martiel JL, Cochet C. Protein kinase CK2: a new view of an old molecular complex. EMBO Rep 2004 ; 5 : 351–355. [CrossRef] [PubMed]
  23. Laudet B, Barette C, Dulery V, et al. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem J 2007 ; 408 : 363–373. [CrossRef] [PubMed]
  24. Laudet B, Prudent R, Filhol O, et al. Des agents thérapeutiques ciblant des interactions protéine-protéine. Med Sci (Paris) 2007 ; 23 : 273–278. [CrossRef] [EDP Sciences] [PubMed]
  25. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov 2014 ; 13 : 588–602. [CrossRef] [PubMed]
  26. Brodin P, Del Nery, Elaine, Soleilhac E. Criblage phénotypique à haut contenu pour la chémobiologie et ses enjeux. Med Sci (Paris) 2015 ; 31 : 187–196. [CrossRef] [EDP Sciences] [PubMed]
  27. Vassal E, Barette C, Fonrose X, et al. Miniaturization and validation of a sensitive multiparametric cell-based assay for the concomitant detection of microtubule-destabilizing and microtubule-stabilizing agents. J Biomol Screen 2006 ; 11 : 377–389. [CrossRef] [PubMed]
  28. Eggert US, Mitchison TJ. Small molecule screening by imaging. Curr Opin Chem Biol 2006 ; 10 : 232–237. [CrossRef] [PubMed]
  29. Korn K, Krausz E. Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol 2007 ; 11 : 503–510. [CrossRef] [PubMed]
  30. Soleilhac E, Nadon R, Lafanechere L. High-content screening for the discovery of pharmacological compounds: advantages, challenges and potential benefits of recent technological developments. Expert Opin Drug Discov 2010 ; 5 : 135–144. [CrossRef] [PubMed]
  31. Martinez A, Soleilhac E, Barette C, et al. Novel synthetic pharmacophores inducing a stabilization of cellular microtubules. Curr Cancer Drug Targets 2014 ; 15 : 2–13. [CrossRef]
  32. Lo E, Soleilhac E, Martinez A, et al. Intensity quantile estimation and mapping: a novel algorithm for the correction of image non-uniformity bias in HCS data. Bioinforma Oxf Engl 2012 ; 28 : 2632–2639. [CrossRef] [PubMed]
  33. Murie C, Barette C, Lafanechere L, et al. Single assay-wide variance experimental (SAVE) design for high-throughput screening. Bioinforma Oxf Engl 2013 ; 29 : 3067–3072. [CrossRef]
  34. Murie C, Barette C, Lafanechère L, et al. Control-plate regression (CPR) normalization for high-throughput screens with many active features. J Biomol Screen 2014 ; 19 : 661–671. [CrossRef] [PubMed]
  35. Murie C, Barette C, Button J, et al. Improving detection of rare biological events in high-throughput screens. J Biomol Screen 2014 ; 20 : 230–241. [CrossRef] [PubMed]
  36. Thomas CJ, Auld DS, Huang R, et al. The pilot phase of the NIH chemical genomics center. Curr Top Med Chem 2009 ; 9 : 1181–1193. [CrossRef] [PubMed]
  37. Voisset C, Blondel M. Chémobiologie à l’happy hour : la levure comme modèle de criblage pharmacologique. Med Sci (Paris) 2014 ; 30 : 1161–1168. [CrossRef] [EDP Sciences] [PubMed]
  38. Mahuteau-Betzer F. Chimiothèque Nationale : avancées et perspectives. Med Sci (Paris) 2015 ; 31 : 417–422. [CrossRef] [EDP Sciences] [PubMed]
  39. Vidalain PO, Lucas-Hourani M, Helynck O, Tangy F, Munier-Lehmann H. Activation de la réponse innée antivirale par des inhibiteurs de la biosynthèse des pyrimidines : les surprises d’un criblage phénotypique. Med Sci (Paris) 2015 ; 31 : 98–104. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.